Xiong Wan
Department of Infections and Digestive, Children's Hospital of Chongqing Medical University, Chongqing, China.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2010 Nov;26(11):1130-2.
To observe the clinical efficacy of treating infant cytomegalovirus (CMV) hepatitis with ganciclovir and impact on cytokines.
76 patients with CMV hepatitis infant were randomly divided into treatment group and control group. The patients of two groups were treated using conventional therapy, on the basis of conventional therapy the treatment group was treated using induction and maintenance treatment of ganciclovir. Before and after treatment the growth and decline in jaundice, liver function, side effects and IL-8 and IFN-γ levels of the patients were detected, clinical efficacy was evaluated.
The clinical total effective rate of the treatment group was 91.4%, it was significantly higher than that of the control group (71.4%), compared with the control group the difference was significant (P < 0.05). After treatment, the growth and decline of jaundice (TBIL and DBIL), liver enzymes (ALT and AST) and cytokines (IL-8 and IFN-γ) levels increased, compared with the pre-treatment and the control group the difference was significant (P < 0.05). The treatment group was no adverse reaction.
The induction and maintenance treatment of ganciclovir in treatment of infant CMV hepatitis can make the body to restore balance of specific cellular immunity, and can significantly improve the symptoms of jaundice, liver function and clinical efficay and it is worthy to be popularized.
观察更昔洛韦治疗婴儿巨细胞病毒(CMV)肝炎的临床疗效及对细胞因子的影响。
将76例婴儿CMV肝炎患者随机分为治疗组和对照组。两组患者均采用常规治疗,治疗组在常规治疗基础上加用更昔洛韦诱导及维持治疗。检测治疗前后患者黄疸的消长、肝功能、不良反应及IL-8和IFN-γ水平,评价临床疗效。
治疗组临床总有效率为91.4%,明显高于对照组(71.4%),与对照组比较差异有统计学意义(P<0.05)。治疗后,黄疸(TBIL和DBIL)、肝酶(ALT和AST)及细胞因子(IL-8和IFN-γ)水平较治疗前及对照组均明显下降,差异有统计学意义(P<0.05)。治疗组无不良反应。
更昔洛韦诱导及维持治疗婴儿CMV肝炎能使机体特异性细胞免疫恢复平衡,能显著改善黄疸症状、肝功能及临床疗效,值得推广。